Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease

Kooij, Monique K. Van der; Suijkerbuijk, Karijn P M; Aarts, Maureen J.B.; Berkmortel, Franchette W P J van den; Blank, Christian U.; Boers‐Sonderen, Marye J.; Breeschoten, Jesper van; Eertwegh, A.J.M. van den; Groot, Jan Willem B. de; Haanen, John B.A.G.; Hospers, Geke A.P.; Piersma, Djura; Rijn, Rozemarijn S. van; Tije, Albert J. ten; Veldt, Astrid A.M. van der; Vreugdenhil, Gerard; Zeijl, Michiel C T van; Wouters, Michel W.J.M.; Dekkers, Olaf M.; Kapiteijn, Ellen

doi:10.7326/m20-3419

Cited by 58 publications

(35 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the 228 patients with select pre-IMID who received ICI, severe irAE development, response, and survival rates were not significantly different between patients with and without pre-IMID. 13 Our findings of improved survival and increased toxicity in pre-IMID patients are in contrast to this study. This is possibly due to inclusion of a more limited number of autoimmune diseases in the previously published study, which focused on inflammatory bowel disease as well as endocrine and rheumatic conditions.…”

Section: Discussioncontrasting

confidence: 99%

Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 99%

Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…More than half of these patients experienced a flare of their prior disorder, whereas less than one-third developed a different irAE. In a more recent study by the Dutch Melanoma Treatment Registry, the rate of irAE was 30% irrespective of the presence of an underlying autoimmune condition [9].…”

Section: Discussionmentioning

confidence: 94%

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma

Thomas

Patel

Scott

2021

Cureus

View full text Add to dashboard Cite

Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literature exists regarding the treatment of patients with pre-existing myositis. We describe a case of myositis flare after initiation of nivolumab for metastatic melanoma in a patient who had previously achieved remission of dermatomyositis.

show abstract

“…It should be noted, however, that there may be a bias toward mild autoimmune disease given that none of the patients were dependent on systemic corticosteroids at baseline. A cohort study by Van der Kooij et al further demonstrated that immune-related adverse events were similar between patients with and without underlying autoimmune disease who were treated for advanced melanoma with immune checkpoint inhibitors [ 8 ]. Importantly, they did report that patients with inflammatory bowel disease were more likely to develop severe colitis and toxicity requiring early discontinuation of treatment.…”

Section: Discussionmentioning

confidence: 99%

Successful Use of Immunotherapy in a Patient with Metastatic Squamous Cell Lung Cancer and Underlying Autoimmune Disease

Zakharian

Lee

2021

Cureus

View full text Add to dashboard Cite

The immune system removes abnormal and cancerous cells by way of T-cell detection at immune checkpoints. Cancerous cells, due to their expression of proteins such as T-cell inactivating programmed death-ligand 1 (PD-L1), may evade the immune system resulting in replication and ultimately metastases. Immunotherapy in the form of checkpoint blockade, such as anti-programmed cell death 1 (PD-1) monoclonal antibody pembrolizumab, targets and interferes with this interaction, thereby restoring T-cell ability to remove cancer cells. Immunotherapy has revolutionized cancer treatment and has improved survival in several malignancies. However, the presence of autoimmune disease is an exclusion criterion for most immunotherapy trials due to fear of potentially life-threatening immune system activation. Therefore, its safety and efficacy in patients with autoimmune disease are not well studied. We describe the successful use of pembrolizumab in a patient with systemic lupus erythematosus (SLE) and review available literature, demonstrating that there is a subset of patients with underlying autoimmune disease who can safely be treated with immunotherapy. Furthermore, that administration of traditional cytotoxic chemotherapy prior to immunotherapy may lead to autoimmune disease control by eliminating autoantibodies.

show abstract

Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease

Abstract: Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Cited by 58 publications

References 27 publications

Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors

Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma

Successful Use of Immunotherapy in a Patient with Metastatic Squamous Cell Lung Cancer and Underlying Autoimmune Disease

Contact Info

Product

Resources

About